An official blog in I3investor to publish research reports provided by RHB Research team.
All materials published here are prepared by RHB Investment Bank Bhd. For latest offers on RHB Invest trading products and news, please refer to: http://www.rhbinvest.com
RHB Investment Bank Bhd Level 3A, Tower One, RHB Centre Jalan Tun Razak Kuala Lumpur Malaysia
Reiterate BUY, new SOP-based TP of MYR7.42 from MYR7.60, 16% upside with c.1% FY22F yield. IHH Healthcare should benefit from the gradual rebound in medical tourism. Medical tourists to Singapore and Malaysia are now at 17% and 1.5% of pre-pandemic levels, following the upliftment of border restrictions in both countries since April. This, on top of the resilient demand for healthcare services, as well as continuing efforts to minimise its exposure to non-TRY revenue (32% of 1H22 total Turkey turnover vs 1H21’s 28%) from its Eastern Europe segment, justifies our call.
Medical tourism yet to return to full potential. IHH expects the recovery of medical tourist numbers to be its key growth driver in the quarters ahead. In 2Q, medical tourists going to Singapore and Malaysia were at 17% and 1.5% of levels recorded prior to COVID-19, ie post reopening of borders in April. As the Singapore segment booked numbers that were stronger than what management anticipated (due to the upswing in foreign patients), we have tweaked our revenue intensity assumption for FY22 to SGD12,848, from SGD12,000.
Impact of MFRS 129 is minimal. We expect IHH’s depreciation and amortisation costs to increase by 4% YoY in 2023, until the effect of MFRS 129 is watered down. Although there could be a potential impairment risk – given the previous higher restated amounts of non-monetary items under MFRS 129 – we regard this as a one-off entry, and somewhat similar to the net monetary gain (amounting to MYR295.5m) observed in 2Q22.
Cash flow. On 27 Jul, IHH completed the redemption of USD500m (MYR2,158m) in perpetual securities via its existing cash balance and loan drawdowns. From the perspective of cash flow, the restructuring exercise will allow the group to pare down its borrowing cost to 3.01% (floating) from 4.25% (fixed), and provide interest payments by up to 50%. Assuming the company applies a 50:50 cash:loan ratio to fund the redemption exercise, our 2022 net gearing ratio assumption would be adjusted to 0.34, from 0.14.
We trim FY22-23F earnings by 9% and 13%,after factoring in higher depreciation charges ahead, as well as a potentially weak topline from its Turkish unit. These, however, should be offset by robust revenue intensity growth from the foreign patient load. Maintain BUY, while our TP drops to MYR7.42. As the ESG score for IHH is on par with our country median, we ascribe a 0% ESG premium or discount to our intrinsic value.
Key downside risks: An unfavourable Supreme Court ruling with regards to the acquisition of Fortis, lower-than-expected patient volumes and revenue intensity, and higher-than-expected operating costs.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....